Universal Beteiligungs und Servicegesellschaft mbH decreased its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 12.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,307,692 shares of the medical equipment provider's stock after selling 190,913 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.09% of Boston Scientific worth $131,920,000 at the end of the most recent quarter.
Other institutional investors have also recently modified their holdings of the company. Guidance Capital Inc. acquired a new stake in Boston Scientific during the 1st quarter worth about $397,000. Hartford Funds Management Co LLC boosted its stake in shares of Boston Scientific by 21.5% in the 1st quarter. Hartford Funds Management Co LLC now owns 7,959 shares of the medical equipment provider's stock valued at $803,000 after purchasing an additional 1,411 shares in the last quarter. Ignite Planners LLC boosted its position in Boston Scientific by 3.8% during the 1st quarter. Ignite Planners LLC now owns 3,905 shares of the medical equipment provider's stock valued at $403,000 after buying an additional 142 shares during the period. HighPoint Advisor Group LLC raised its stake in Boston Scientific by 0.6% in the first quarter. HighPoint Advisor Group LLC now owns 20,554 shares of the medical equipment provider's stock worth $2,112,000 after buying an additional 125 shares in the last quarter. Finally, Crestwood Advisors Group LLC raised its holdings in Boston Scientific by 19.9% in the first quarter. Crestwood Advisors Group LLC now owns 81,418 shares of the medical equipment provider's stock worth $8,213,000 after purchasing an additional 13,490 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.
Insider Activity at Boston Scientific
In other news, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $103.69, for a total value of $17,051,094.67. Following the completion of the sale, the chief executive officer owned 1,476,882 shares of the company's stock, valued at approximately $153,137,894.58. This represents a 10.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,314 shares of the firm's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $102.06, for a total value of $1,767,066.84. Following the completion of the transaction, the executive vice president owned 22,235 shares in the company, valued at $2,269,304.10. The trade was a 43.78% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 457,144 shares of company stock valued at $47,296,288. 0.50% of the stock is owned by company insiders.
Analyst Ratings Changes
A number of equities analysts recently issued reports on BSX shares. Barclays raised their price objective on shares of Boston Scientific from $118.00 to $125.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Robert W. Baird increased their price target on Boston Scientific from $115.00 to $120.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Jefferies Financial Group reaffirmed a "hold" rating on shares of Boston Scientific in a research report on Monday. Needham & Company LLC reiterated a "buy" rating and set a $115.00 price objective on shares of Boston Scientific in a research note on Wednesday, May 28th. Finally, BTIG Research reiterated a "buy" rating and issued a $124.00 target price on shares of Boston Scientific in a research note on Wednesday, April 23rd. One research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $116.04.
Read Our Latest Stock Report on Boston Scientific
Boston Scientific Trading Up 0.2%
Boston Scientific stock traded up $0.16 during trading on Tuesday, hitting $103.94. The company had a trading volume of 1,277,969 shares, compared to its average volume of 6,728,909. The company has a current ratio of 1.45, a quick ratio of 0.88 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a 1-year low of $71.88 and a 1-year high of $107.53. The stock has a market cap of $153.77 billion, a price-to-earnings ratio of 75.95, a price-to-earnings-growth ratio of 2.69 and a beta of 0.68. The company's 50 day simple moving average is $103.42 and its 200-day simple moving average is $101.16.
Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.08. The business had revenue of $4.66 billion for the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. The company's quarterly revenue was up 20.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.56 earnings per share. As a group, analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.
Boston Scientific Company Profile
(
Free Report)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Boston Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.
While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report